This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
by Zacks Equity Research
A low key week for the biotech sector with focus on regular pipeline updates.
Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis
by Zacks Equity Research
Biogen (BIIB) obtains a license to develop and commercialize BIIB067 from Ionis Pharmaceuticals. The candidate is being developed for treatment of ALS with SOD1 mutations.
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 76.92% and 9.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA
by Zacks Equity Research
Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.
Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study
by Zacks Equity Research
Pfizer's (PFE) tafamidis significantly reduces rate of mortality and cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy. However, it fails to impress investors. Stock dips.
Ionis Pharmaceuticals (IONS) Looks Good: Stock Adds 7.8% in Session
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -150.00% and -8.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Ionis (IONS) Posts Wider than Expected Loss in Q2, Sales Miss
by Zacks Equity Research
Ionis posts wider than expected loss and sales miss estimates in the second quarter of 2018.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
On Ionis' (IONS) second-quarter 2018 conference call, investor focus will remain on the company's progress with the pipeline candidates as well as royalty revenues earned from Spinraza.
Biogen (BIIB) Q2 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Biogen (BIIB) beats estimates on both counts in the second quarter. The company's multiple sclerosis drugs' sales up sequentially amid competition.
Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
by Zacks Equity Research
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Regulus Stock Plunges on Cash Concerns Despite Restructuring
by Zacks Equity Research
Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.
Pfizer's Tafamadis Gets Breakthrough Therapy Designation
by Zacks Equity Research
Pfizer's (PFE) rare disease candidate, tafamidis, gets Breakthrough Therapy designation in the United States for the treatment of transthyretin cardiomyopathy.
Ionis (IONS) Beats Earnings & Misses Revenues in Q1
by Zacks Equity Research
Ionis Pharmaceutical (IONS) reported positive quarter with earnings beating estimates while revenues missing the same.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.
Ionis Pharmaceuticals (IONS) in Focus: Stock Moves 5.8% Higher
by Zacks Equity Research
Shares of Ionis Pharmaceuticals (IONS) rose 5.8% on Friday.
Ionis (IONS) Clinches Licensing Agreement with AstraZeneca
by Zacks Equity Research
Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.
Alnylam Falls on Pfizer's Rare Disease Drug Success
by Zacks Equity Research
Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.
Pfizer's Rare Disease Candidate Meets Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.
Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer
by Zacks Equity Research
Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).
Ionis (IONS) Beats Both Earnings & Revenues in Q4
by Zacks Equity Research
Ionis Pharmaceutical (IONS) reported positive quarter with earnings and revenues beating estimates.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.
Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.